Immutep S.a.s. is a biotechnology company based in Orsay, France, specializing in the development of innovative immunotherapy solutions for cancer and autoimmune diseases. The company focuses on harnessing the power of the immune system to create treatments that enhance patient outcomes. With a strong emphasis on research and development, Immutep is dedicated to advancing its proprietary technologies, particularly in the field of LAG-3 (Lymphocyte Activation Gene-3), which plays a crucial role in immune regulation.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

10 Patents

#6 in Orsay

#1,710 in France

#55,986 in the World

Orsay, France

Immutep S.a.s.

Forward Citations = 33

9 inventors:

Chrystelle Brignone (8 out of 9 patents)

Frederic Triebel (5 out of 26 patents)

Frédéric Triebel (4 out of 7 patents)

4. Hwai Wen Chang (3 out of 58 patents)

5. Gerhard Johann Frey (3 out of 87 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Immutep S.a.s.. Retrieved from https://idiyas.com/company/immutep-s-a-s

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

1 patent (CIPO):

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

8 patents (EPO):

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]